EyePoint Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EyePoint Pharmaceuticals, Inc. - overview
Established
1987
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 1987, Eyepoint Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on ophthalmology, developing and marketing ophthalmic products used by patients with serious eye disorders. In October 2024, EyePoint Pharmaceuticals, Inc. raised approximately USD 151.
1 million in a public offering, selling 12. 7 million shares at USD 11. 00 per share on the Nasdaq Capital Market. EyePoint Pharmaceuticals, Inc.
has granted the underwriters a 30-day option to purchase up to an additional 1. 9 million shares of common stock as part of the listing. EyePoint Pharmaceuticals, Inc. develops, and markets ophthalmic products used by patients with serious eye disorders.
It offers Durasert, an injectable that is capable of local sustained delivery of drug products. It is capable of providing sustained release of therapeutics in the eye over a period of weeks, months, or years. Another product it offers is Verisome which is also a sustained-delivery platform that is a biodegradable liquid in an aqueous sphere. Duration is customizable from one week to several months.
Current Investors
EW Healthcare Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Optometrists & Opticians Products and Services, Specialty Pharmaceuticals
Website
www.eyepointpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
EyePoint Pharmaceuticals, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | EyePoint Pharmaceuticals, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | EyePoint Pharmaceuticals, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | EyePoint Pharmaceuticals, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | EyePoint Pharmaceuticals, Inc. | - | ||||||||
| PIPE | Completed | EyePoint Pharmaceuticals, Inc. | - |
Displaying 1 - 5 of 6
EyePoint Pharmaceuticals, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.